https://scholars.lib.ntu.edu.tw/handle/123456789/584894
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | ANDY SUN | en_US |
dc.contributor.author | JULIA YU-FONG CHANG | en_US |
dc.contributor.author | JEAN-SAN CHIA | en_US |
dc.contributor.author | CHUN-PIN CHIANG | en_US |
dc.date.accessioned | 2021-10-15T08:26:51Z | - |
dc.date.available | 2021-10-15T08:26:51Z | - |
dc.date.issued | 2004 | - |
dc.identifier.issn | 0904-2512 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-1342323946&partnerID=40&md5=09665a37742c5aa4e6964b4c952cf90c | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/584894 | - |
dc.description.abstract | BACKGROUND: Recurrent aphthous ulcerations (RAU) are common oral inflammatory lesions. Interleukin (IL)-8 is a pro-inflammatory cytokine of host response to injury and inflammation. Our recent study has found that measurement of serum IL-6 level can detect only 24% RAU patients with an abnormal serum level. In this study, we examined both the serum IL-6 and IL-8 levels in a group of RAU patients. The abilities of IL-6 and IL-8 to detect patients with an abnormal serum level were compared in order to find out whether IL-8 was a more sensitive serum marker than IL-6 in monitoring the disease activity of RAU. METHODS: In this study, we used a solid-phase, two-site sequential chemiluminescent immunometric assay to determine the baseline serum levels of IL-6 and IL-8 in 146 patients with RAU, 9 patients with traumatic ulcers (TU), and 54 normal control (NC) subjects. Eighty-two RAU patients, with the serum IL-6 or IL-8 levels higher than the upper limit of normal serum concentration, were treated with levarnisole for 0.5-3.5 months, and their serum IL-6 and IL-8 levels were measured after treatment. RESULTS: We found that 25% (37/146) RAU patients, as well as 33% (20/61) major-type, 19% (13/69) minor-type, and 25% (4/16) herpetiform-type RAU patients, had a serum level of IL-6 greater than the upper normal limit of 4.7 pg/ml. In contrast, 60% (87/146) RAU patients, as well as 59% (36/61) major-type, 59% (41/69) minor-type, and 63% (10/16) herpetiform-type RAU patients, had a serum level of IL-8 greater than the upper normal limit of 8.7 pg/ml. In 82 RAU patients with the serum IL-6 or IL-8 levels higher than the upper limit of normal serum concentration, treatment with levamisole for a period of 0.5-3.5 months could significantly reduce the serum IL-6 level from 12.0 ± 1.6 to 3.0 ± 0.5 pg/ml (P < 0.00 1), and could significantly lower the serum IL-8 level from 70.9 ± 11.2 to 13.8 ± 3.1 pg/ml (P < 0.001). CONCLUSIONS: Because measurement of serum IL-8 level can detect 60% RAU patients with an abnormal serum level, while measurement of serum IL-6 level can detect only 25% RAU patients with an abnormal serum level, we conclude that serum IL-8 level is a more sensitive marker than serum IL-6 level in monitoring the disease activity of RAU. Levamisole can modulate both the serum IL-6 and IL-8 levels in RAU patients. IL-8, like IL-6, is also a useful serum marker in evaluating therapeutic effects of levamisole on RAU patients. | en_US |
dc.relation.ispartof | Journal of Oral Pathology and Medicine | en_US |
dc.subject | Interleukin-6; Interleukin-8; Levamisole; Recurrent aphthous ulcerations | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | biological marker; interleukin 6; interleukin 8; levamisole; serum marker; unclassified drug; adolescent; adult; aged; aphthous ulcer; aphthous ulcer herpetiform type; aphthous ulcer major type; aphthous ulcer minor type; article; blood level; chemoluminescence; child; controlled study; diagnostic accuracy; disease activity; drug response; female; human; immunoassay; inflammation; major clinical study; male; monitoring; priority journal; Adolescent; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Biological Markers; Case-Control Studies; Child; Female; Humans; Interleukin-6; Interleukin-8; Levamisole; Male; Middle Aged; Sensitivity and Specificity; Stomatitis, Aphthous | - |
dc.title | Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of recurrent aphthous ulcerations | en_US |
dc.type | journal article | en |
dc.identifier.pmid | 15128054 | - |
dc.identifier.scopus | 2-s2.0-1342323946 | - |
dc.relation.pages | 133-139 | en_US |
dc.relation.journalvolume | 33 | en_US |
dc.relation.journalissue | 3 | en_US |
item.cerifentitytype | Publications | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairetype | journal article | - |
item.grantfulltext | none | - |
crisitem.author.dept | Dentistry | - |
crisitem.author.dept | Dentistry-NTUH | - |
crisitem.author.dept | School of Dentistry | - |
crisitem.author.dept | Clinical Dentistry | - |
crisitem.author.dept | Clinical Medicine | - |
crisitem.author.dept | Oral Biology | - |
crisitem.author.dept | Microbiology | - |
crisitem.author.dept | Dentistry-NTUH | - |
crisitem.author.dept | School of Dentistry | - |
crisitem.author.dept | Oral Biology | - |
crisitem.author.orcid | 0000-0002-4912-5424 | - |
crisitem.author.orcid | 0000-0002-3880-3787 | - |
crisitem.author.orcid | 0000-0002-5431-0712 | - |
crisitem.author.orcid | 0000-0002-6190-7162 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
顯示於: | 牙醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。